US health authorities have authorized a new anti-migraine treatment which has the particularity of being administered by a nasal aerosol, the pharmaceutical giant Pfizer announced on Friday.
The treatment, which will be marketed by the American laboratory under the name of Zavzpret, has been authorized for the treatment of severe migraines in adults.
In a large clinical trial, the results of which were published last month in the scientific journal Lancet Neurology, the drug demonstrated positive pain-relieving effects over a placebo, sometimes as quickly as 15 minutes after a dose. , pointed out Pfizer.
“One of the most important characteristics of an acute treatment option is how quickly it works,” said Kathleen Mullin of the New England Institute for Neurology & Headache, quoted in the Pfizer statement.
“As a nasal spray with rapid absorption, Zavzpret offers an alternative treatment option for those in need of relief who cannot take oral medications, due to nausea or vomiting,” she said. added.
Migraines can have a significant effect on daily life, and are often accompanied, in addition to headaches, by visual disturbances or an intolerance to light.
Pfizer has specified that the treatment will be available in American pharmacies in July 2023. The molecule used is called zavegepant.
The American giant bought Biohaven a year ago for more than ten billion dollars, the company that develops zavegepant and other migraine treatments.
